Skip to main content

Keto and Type 2 Diabetes: Evidence, Limits & Safety Questions

A ketogenic eating pattern can be one option for an adult with type 2 diabetes, but it is not a self-directed medication plan or a cure. Current American Diabetes Association (ADA) guidance finds that carbohydrate-restricted patterns can improve A1C in the short term for some people, while differences between eating patterns often narrow after one year. The same guidance calls for regular medical oversight of very-low-carbohydrate plans because diabetes treatment, blood pressure, clinical history, and food access all affect safety.1

This page explains the decision rather than prescribing it. It does not give carbohydrate targets, medication doses, a stop-or-continue rule, or a food list for a person with diabetes. Those choices belong in a plan made with the clinician who prescribes your treatment and, where available, a registered dietitian nutritionist or diabetes care and education specialist.

What does the current evidence actually support?​

The ADA includes low-carbohydrate eating patterns among the evidence-based options for type 2 diabetes. It does not identify one ideal carbohydrate, protein, or fat distribution for everyone. Nutrition care should reflect a person’s health goals, preferences, culture, access to food, ability to make changes, and other barriers.1

For very-low-carbohydrate patterns, the evidence has limits worth stating plainly. The ADA’s 2026 review reports short-term A1C reductions in systematic reviews and meta-analyses of randomized trials, particularly before six months, with less separation from other eating patterns beyond one year. It also cites a 12-week randomized trial in which a ketogenic pattern did not significantly improve A1C and increased LDL cholesterol compared with a low-carbohydrate Mediterranean pattern.1

That is why this guide does not promise a particular A1C change, weight change, medication outcome, or timeline. A lower-carbohydrate approach may be useful for some people; sustained benefit and risk need to be evaluated against the alternatives a person can actually follow.

Does keto reverse or cure type 2 diabetes?​

No. This article does not use “reversal” or “cure” to describe keto. Better glucose results can be clinically meaningful, but they do not replace ongoing diabetes care or make a person’s medication, cardiovascular, kidney, hypoglycemia, and nutrition needs disappear.

ADA guidance asks clinicians and people with diabetes to set glycemic goals through shared decision-making. Those goals are individualized according to health, function, hypoglycemia risk, treatment burden, resources, and preferences.2 Medication choices likewise need a person-centered review of comorbidities, adverse effects, treatment burden, and goals.3

Why medications change the safety question​

Changing carbohydrate intake can change glucose exposure. That matters most for therapies that can cause hypoglycemia, including insulin and some insulin-secreting medications. The ADA says health professionals should maintain consistent medical oversight for people following very-low-carbohydrate plans and recognize that insulin and other diabetes medicines may need adjustment to prevent hypoglycemia.1

Medication oversight is required before changing the pattern. Do not use an article, a macro calculator, or another person’s medication experience to decide what you should start, stop, or change. The same applies to blood-pressure treatment and to any monitoring plan.

SGLT2 inhibitors need a separate conversation​

SGLT2 inhibitors are a distinct class of glucose-lowering medicines. The ADA advises avoiding very-low-carbohydrate eating plans in people taking an SGLT2 inhibitor because of ketoacidosis risk.1 Its pharmacologic-treatment guidance also says people at risk for diabetic ketoacidosis who use SGLT inhibition should be educated about that risk and discouraged from a ketogenic eating pattern.3

Current FDA labeling for dapagliflozin identifies a ketogenic diet as a precipitating condition for ketoacidosis. It also notes that symptoms can occur with glucose below the level people may expect in diabetic ketoacidosis.4 If you use an SGLT2 inhibitor, raise keto specifically with your prescriber before you change your eating pattern. This page cannot decide whether that medication is appropriate for you.

Nutritional ketosis and diabetic ketoacidosis are different, but symptoms still matter​

Nutritional ketosis from carbohydrate restriction and diabetic ketoacidosis (DKA) are not the same condition. DKA is a serious, acute, life-threatening hyperglycemic crisis that requires immediate medical care; it is a clinical diagnosis, not a conclusion that can be drawn from a keto diet label or a single home reading.2

The distinction must not make people dismiss warning signs. FDA labeling lists nausea, vomiting, abdominal pain, generalized malaise, and shortness of breath among symptoms consistent with severe metabolic acidosis. Seek urgent medical assessment for those symptoms, particularly with known or possible diabetes, even if a glucose reading does not look markedly high.4

Illness, surgery, reduced intake, dehydration, alcohol use, insulin deficiency, and SGLT2 inhibitor use can alter risk. In people with type 2 diabetes taking SGLT2 inhibitors, ADA guidance identifies very-low-carbohydrate diets and prolonged fasting among DKA risk factors.2

Who should not treat this as a standard keto-start guide?​

The ADA states that very-low-carbohydrate eating plans are not currently recommended for people who are pregnant or lactating, children, people with kidney disease, or people with or at risk for disordered eating.1 A person with type 1 diabetes, a past hyperglycemic crisis, suspected insulin deficiency, or a complex medication regimen also needs condition-specific clinical guidance rather than a general keto tutorial.

This page is written for adults discussing type 2 diabetes with a care team. It is not a protocol for pregnancy, pediatric care, type 1 diabetes, an acute illness, or an emergency.

What does a clinically useful discussion look like?​

Bring the idea to an appointment as a decision to evaluate, not as a diet challenge already underway. A useful conversation covers:

  • your current diagnosis, A1C or glucose information, symptoms, and relevant medical history;
  • every prescription medicine and over-the-counter product you use, including whether an SGLT2 inhibitor is involved;
  • the risk of hypoglycemia, ketoacidosis, dehydration, blood-pressure changes, and treatment burden in your situation;
  • your food preferences, cultural eating pattern, budget, cooking access, and whether a restrictive pattern is realistically sustainable; and
  • the follow-up and sick-day guidance the clinical team wants you to use.

The ADA supports diabetes self-management education and support, medical nutrition therapy, goal setting, and problem-solving as parts of ongoing care.1 A care team can turn those general principles into a plan without asking you to improvise medication decisions from online guidance.

Food quality still matters on a lower-carbohydrate pattern​

Keto does not make diet quality irrelevant or turn diabetes care into a universal allowed-or-forbidden-food list. The ADA’s nutrition goals emphasize a variety of nutrient-dense foods in appropriate portions and practical healthy eating patterns rather than isolated macronutrients or single foods.1

If a clinician-approved lower-carbohydrate pattern is being considered, use the Food Database to inspect a food’s form, serving, fiber, and source-recorded nutrients. The keto food list and meal-planning guide can help readers understand general keto concepts, but neither can determine a diabetes-safe meal or medication plan.

How keto compares with other options​

ADA guidance includes several evidence-based eating patterns for type 2 diabetes and favors individualized nutrition therapy over a universal macronutrient formula.1 A lower-carbohydrate plan may fit one person’s priorities; a Mediterranean-style, plant-forward, DASH-style, or another individualized pattern may fit another person better.

Use a practical comparison: which option has a credible safety plan, supports the person’s glycemic and cardiometabolic goals, and fits their life? This is the shared decision-making question, rather than a claim that one dietary label works for everyone.

For the physiology behind ketosis, read the science of ketosis. For a general suitability screen that does not replace clinical care, see Is keto right for you?.

Frequently Asked Questions

Can an adult with type 2 diabetes use keto?
Possibly, but it is an individualized nutrition and treatment decision. Current ADA guidance treats low-carbohydrate patterns as one option, not as a universal diabetes treatment or a substitute for clinical care.
Can keto cure or reverse type 2 diabetes?
No. This guide does not describe keto as a cure or reversal. Changes in glucose outcomes can be meaningful, but goals, medicines, and follow-up still need individualized diabetes care.
What if I take insulin or another glucose-lowering medicine?
A carbohydrate change can affect glucose exposure and treatment safety. Ask the clinician who prescribes your medicine to review the plan before changing your eating pattern; this page does not provide medication instructions.
What if I take an SGLT2 inhibitor?
Discuss keto with your prescriber before changing your diet. ADA guidance advises against very-low-carbohydrate patterns in people taking SGLT2 inhibitors because of ketoacidosis risk.
When are symptoms urgent?
Nausea, vomiting, abdominal pain, generalized malaise, or shortness of breath can signal serious illness. Seek urgent medical assessment, particularly with known or possible diabetes, even if a glucose reading does not seem very high.
Does this page tell me which foods to eat?
No. It explains why a narrow food list is not a diabetes treatment plan. Food choices, portions, and carbohydrate amount should be agreed with the care team that knows your medical history and treatment.

Works cited​

  1. American Diabetes Association Professional Practice Committee. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl. 1):S89–S131. Accessed August 25, 2026. https://diabetesjournals.org/care/article/49/Supplement_1/S89/163932/5-Facilitating-Positive-Health-Behaviors-and-Well
  2. American Diabetes Association Professional Practice Committee. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl. 1):S132–S149. Accessed August 25, 2026. https://diabetesjournals.org/care/article/49/Supplement_1/S132/163927/6-Glycemic-Goals-Hypoglycemia-and-Hyperglycemic
  3. American Diabetes Association Professional Practice Committee. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl. 1):S183–S215. Accessed August 25, 2026. https://diabetesjournals.org/care/article/49/Supplement_1/S183/163934/9-Pharmacologic-Approaches-to-Glycemic-Treatment
  4. U.S. Food and Drug Administration. FARXIGA (dapagliflozin) prescribing information, revised June 2026. Accessed August 25, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/202293s035lbl.pdf

Article history

  1. Rewrote clinical safety guidance using ADA 2026 standards and current FDA SGLT2 labeling; removed individualized medication and food prescriptions
  2. First published

Your learning guide

Loading reading status…